Eslam Maher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eslam Maher has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Moatasem El-Ayadi
Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
8 shared publications - Mohamed Saad Zaghloul
Department of Radiation Oncology, Children’s Cancer Hospital Egypt, Cancer, Cairo, Egypt
7 shared publications - Abdelrahman Enayet
Department of Neurosurgery, Children’s Cancer Hospital, Cairo, Egypt
6 shared publications - Amal Refaat
Department of Radiology, Children’s Cancer Hospital, Cairo, Egypt
6 shared publications - Eman Eldebawy
Department of Radiation Oncology, Children’s Cancer Hospital, Cairo, Egypt
6 shared publications - Hala Taha
Department of Mathematical Sciences, College of Science, Princess Nourah Bint Abdulrahman University, P. O. Box 84428, Riyadh 11671, Saudi Arabia
6 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in BJU International
- Vol. 138 (4) , 705-713
Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy ( IB1 ‐ LaserComplete study)
Objectives: To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods: This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive bladder cancer between September 2024 and September 2025 (IB1‐LaserComplete study; International Standard Randomised Controlled Trial Number Register [ISRCTN]16114765). Ex vivo FCM generates immediate high‐resolution digital images of fresh tissue, enabling immediate DM assessment. Intraoperative ex vivo FCM imaging of en face tumour base specimens was performed using the Histolog® scanner (SamanTree Medical SA, Lausanne, Switzerland). DM status was reported by a blinded uro‐pathologist and urologist. Formalin‐fixed histopathology served as the reference standard. The primary outcome was technical feasibility, defined as acquisition of an interpretable FCM image. Secondary outcomes included exploratory diagnostic performance, inter‐observer agreement and time to confirmation of DM status. Results: A total of 34 patients were recruited and 30 had evaluable paired specimens. DM was absent in 13% (four of 30). FCM was sufficient for determining DM status in all patients (100%; 30 of 30). Sensitivity, specificity, positive predictive value, negative predictive value (NPV) were 42% (95% confidence interval [CI] 26–61%), 100% (95% CI 51–100%), 100% (95% CI 74–100%), and 21% (95% CI 9–43%), respectively. Inter‐observer agreement between the uro‐pathologist and urologist was high at 83% (κ = 0.72, 95% CI 0.47–0.97). The median (interquartile range) time to confirm DM status was 5.4 (4.95–5.39) min vs 11 (7–13.8) days using standard histopathology. Conclusion: Fluorescence confocal microscopy is feasible for rapid intraoperative imaging of TURBT specimens and demonstrates excellent specificity for detection of DM. However, its low sensitivity and NPV preclude use as a stand‐alone tool to exclude DM intraoperatively. Based on these findings, FCM should not guide intraoperative decision making outside research settings.
- 13 August 2026
- Published by Wiley in BJU International
- Vol. 138 (4) , 705-713
Open AccessImmediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy ( IB1 ‐ LaserComplete study)
Objectives: To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods: This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive bladder cancer between September 2024 and September 2025 (IB1‐LaserComplete study; International Standard Randomised Controlled Trial Number Register [ISRCTN]16114765). Ex vivo FCM generates immediate high‐resolution digital images of fresh tissue, enabling immediate DM assessment. Intraoperative ex vivo FCM imaging of en face tumour base specimens was performed using the Histolog® scanner (SamanTree Medical SA, Lausanne, Switzerland). DM status was reported by a blinded uro‐pathologist and urologist. Formalin‐fixed histopathology served as the reference standard. The primary outcome was technical feasibility, defined as acquisition of an interpretable FCM image. Secondary outcomes included exploratory diagnostic performance, inter‐observer agreement and time to confirmation of DM status. Results: A total of 34 patients were recruited and 30 had evaluable paired specimens. DM was absent in 13% (four of 30). FCM was sufficient for determining DM status in all patients (100%; 30 of 30). Sensitivity, specificity, positive predictive value, negative predictive value (NPV) were 42% (95% confidence interval [CI] 26–61%), 100% (95% CI 51–100%), 100% (95% CI 74–100%), and 21% (95% CI 9–43%), respectively. Inter‐observer agreement between the uro‐pathologist and urologist was high at 83% (κ = 0.72, 95% CI 0.47–0.97). The median (interquartile range) time to confirm DM status was 5.4 (4.95–5.39) min vs 11 (7–13.8) days using standard histopathology. Conclusion: Fluorescence confocal microscopy is feasible for rapid intraoperative imaging of TURBT specimens and demonstrates excellent specificity for detection of DM. However, its low sensitivity and NPV preclude use as a stand‐alone tool to exclude DM intraoperatively. Based on these findings, FCM should not guide intraoperative decision making outside research settings.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- Open Access
Clinical and Molecular Characteristics of 100 Atypical Teratoid Rhabdoid Tumor Patients from Low- and Middle-Income Countries
Background: Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive, rare pediatric central nervous system malignancy. Prognostic factors for optimizing risk stratification and management in a large uniformly treated cohort are lacking. Methods: We conducted a single-center retrospective cohort study analyzing clinical and outcome data for 100 newly diagnosed ATRT patients aged p = 0.047 and p = 0.002, respectively); however, only metastatic disease had a significantly negative effect on overall survival (OS) and cumulative incidence of relapse (CIR) (p = 0.002 for OS and p < 0.001 for CIR). DNA methylation was performed for 69 patients who were classified as having a TYR (n = 13), SHH (n = 34), MYC (n = 17), or non-ATRT diagnosis (n = 5). In the cohort of the 64 patients with ATRT defined by methylation, no significant survival differences were observed. Treatment-related deaths were reported in 28% of our studied group. Gram-negative septicemia was the most common cause of toxic death. The 5-year EFS and OS of the whole cohort were 12% and 13%, respectively. Conclusions: In this cohort, no significant survival differences were observed among the methylation subgroups. The higher treatment-related mortality in our cohort compared to the original protocol’s toxic-related deaths suggested that intensive and lengthy chemotherapy regimens may need modification for our population. The need for a short intensified approach, including a limited induction cycle followed by an intensified high-dose consolidation therapy, may be more appropriate for our patients with low socioeconomic status to avoid a repeated and prolonged course of protracted neutropenia.
Open AccessClinical and Molecular Characteristics of 100 Atypical Teratoid Rhabdoid Tumor Patients from Low- and Middle-Income Countries
Background: Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive, rare pediatric central nervous system malignancy. Prognostic factors for optimizing risk stratification and management in a large uniformly treated cohort are lacking. Methods: We conducted a single-center retrospective cohort study analyzing clinical and outcome data for 100 newly diagnosed ATRT patients aged p = 0.047 and p = 0.002, respectively); however, only metastatic disease had a significantly negative effect on overall survival (OS) and cumulative incidence of relapse (CIR) (p = 0.002 for OS and p < 0.001 for CIR). DNA methylation was performed for 69 patients who were classified as having a TYR (n = 13), SHH (n = 34), MYC (n = 17), or non-ATRT diagnosis (n = 5). In the cohort of the 64 patients with ATRT defined by methylation, no significant survival differences were observed. Treatment-related deaths were reported in 28% of our studied group. Gram-negative septicemia was the most common cause of toxic death. The 5-year EFS and OS of the whole cohort were 12% and 13%, respectively. Conclusions: In this cohort, no significant survival differences were observed among the methylation subgroups. The higher treatment-related mortality in our cohort compared to the original protocol’s toxic-related deaths suggested that intensive and lengthy chemotherapy regimens may need modification for our population. The need for a short intensified approach, including a limited induction cycle followed by an intensified high-dose consolidation therapy, may be more appropriate for our patients with low socioeconomic status to avoid a repeated and prolonged course of protracted neutropenia.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500023
Expanding the Pediatric Neuro-Oncology Teleconference Experience: From Twinning to International Cases Discussions
PURPOSE: Video teleconferencing in neuro-oncology is feasible and sustainable. The well-established, 20-year long monthly teleconference between King Hussein Cancer Center (KHCC), Jordan, and SickKids, Canada, is an example. Since 2018, several regional centers joined these meetings to discuss their patients' management plans. We aim to evaluate this experience. METHODS: We reviewed the minutes of 56 meetings (2018-2023). Preconference local treatment plans were compared with postconference recommendations. We documented the implementation of recommendations and the impact perceived by the treating oncologists. RESULTS: Two hundred fifty-one patients were discussed: 137 from Jordan and 114 from eight other countries. Four of the 14 participating oncologists had formal pediatric neuro-oncology training. Of the 227 patients (90%), where the local multidisciplinary team had suggested a preconference plan, the teleconference recommendations concurred with the proposed plan in 50% of cases, agreed on it and proposed an alternative option in 18%, and disagreed in 32%. The difference in recommendations mostly affected the proposed treatment modality. In 64% of discordant plans and 50% of alternative plans, the treating team applied the recommendations. The main challenges in applying the recommendations were attributed to patient-related factors (51%), local team consensus on a different plan (26%), or logistic difficulties (23%). The high patient load, longer involvement in teleconferencing, formal neuro-oncology training, and well-established multidisciplinary team helped the KHCC team formulate more concordant plans. CONCLUSION: This experience illustrates the potential benefit for physicians to get an expert opinion on challenging cases. The participating oncologists valued the shared educational experience, especially those related to molecular testing and treatment implications. Joining such regional teleconferences is of particular importance to centers with small patient volume or those lacking a pediatric neuro-oncologist.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500023
Expanding the Pediatric Neuro-Oncology Teleconference Experience: From Twinning to International Cases Discussions
PURPOSE: Video teleconferencing in neuro-oncology is feasible and sustainable. The well-established, 20-year long monthly teleconference between King Hussein Cancer Center (KHCC), Jordan, and SickKids, Canada, is an example. Since 2018, several regional centers joined these meetings to discuss their patients' management plans. We aim to evaluate this experience. METHODS: We reviewed the minutes of 56 meetings (2018-2023). Preconference local treatment plans were compared with postconference recommendations. We documented the implementation of recommendations and the impact perceived by the treating oncologists. RESULTS: Two hundred fifty-one patients were discussed: 137 from Jordan and 114 from eight other countries. Four of the 14 participating oncologists had formal pediatric neuro-oncology training. Of the 227 patients (90%), where the local multidisciplinary team had suggested a preconference plan, the teleconference recommendations concurred with the proposed plan in 50% of cases, agreed on it and proposed an alternative option in 18%, and disagreed in 32%. The difference in recommendations mostly affected the proposed treatment modality. In 64% of discordant plans and 50% of alternative plans, the treating team applied the recommendations. The main challenges in applying the recommendations were attributed to patient-related factors (51%), local team consensus on a different plan (26%), or logistic difficulties (23%). The high patient load, longer involvement in teleconferencing, formal neuro-oncology training, and well-established multidisciplinary team helped the KHCC team formulate more concordant plans. CONCLUSION: This experience illustrates the potential benefit for physicians to get an expert opinion on challenging cases. The participating oncologists valued the shared educational experience, especially those related to molecular testing and treatment implications. Joining such regional teleconferences is of particular importance to centers with small patient volume or those lacking a pediatric neuro-oncologist.
- Open Access
- 10 June 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 174 (3) , 689-697
Impact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma
Purpose: Medulloblastoma (MB) treatment includes surgery, irradiation, and chemotherapy (CT). Cisplatin-based regimens for standard-risk (SR) MB are effective but associated with significant toxicities, particularly ototoxicity. This study compares the toxicity profiles of two CT regimens, focusing on grade ≥ 3 ototoxicity, hematologic, hepatic, renal, and neurologic toxicities. Methods: This study included SR-MB patients aged 3–18 years. Cohort A (2016–2019) received adjuvant CT adopted from the Children’s Oncology Group (COG) A9961 Regimen A protocol, with data collected retrospectively. Cohort B (2020–July 2022) received CT adopted from the ACNS0331 protocol, with data collected prospectively. Toxicities were assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results: A total of 168 patients aged 3 to 18 years were enrolled, 112 (67%) in cohort A and 56 (33%) in cohort B. Grade ≥ 3 ototoxicity was significantly higher in cohort A (24% vs. 3.6%, p < 0.001). Neurotoxicity occurred in 26% vs. 12.5% (p = 0.046). Anemia and thrombocytopenia in 71% vs. 52% (p = 0.04). Febrile neutropenia was more common in cohort B (66% vs. 38%, p < 0.001). No significant differences were found in grade ≥ 3 leukopenia, nephrotoxicity or hepatotoxicity. The 2-year overall survival was 96.4% (95% CI: 93.1–99.9) in cohort A vs. 86.6% (95% CI: 77.8–96.4) in cohort B (p = 0.11). Event-free survival was 92.9% (95% CI: 88.2–97.8) vs. 86.8% (95% CI: 78-96.4) (p = 0.29). Conclusion: Partial substitution of cisplatin with cyclophosphamide showed a better toxicity profile, particularly for ototoxicity and neurotoxicity, with no significant difference in survival.
- 10 June 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 174 (3) , 689-697
Open AccessImpact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma
Purpose: Medulloblastoma (MB) treatment includes surgery, irradiation, and chemotherapy (CT). Cisplatin-based regimens for standard-risk (SR) MB are effective but associated with significant toxicities, particularly ototoxicity. This study compares the toxicity profiles of two CT regimens, focusing on grade ≥ 3 ototoxicity, hematologic, hepatic, renal, and neurologic toxicities. Methods: This study included SR-MB patients aged 3–18 years. Cohort A (2016–2019) received adjuvant CT adopted from the Children’s Oncology Group (COG) A9961 Regimen A protocol, with data collected retrospectively. Cohort B (2020–July 2022) received CT adopted from the ACNS0331 protocol, with data collected prospectively. Toxicities were assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results: A total of 168 patients aged 3 to 18 years were enrolled, 112 (67%) in cohort A and 56 (33%) in cohort B. Grade ≥ 3 ototoxicity was significantly higher in cohort A (24% vs. 3.6%, p < 0.001). Neurotoxicity occurred in 26% vs. 12.5% (p = 0.046). Anemia and thrombocytopenia in 71% vs. 52% (p = 0.04). Febrile neutropenia was more common in cohort B (66% vs. 38%, p < 0.001). No significant differences were found in grade ≥ 3 leukopenia, nephrotoxicity or hepatotoxicity. The 2-year overall survival was 96.4% (95% CI: 93.1–99.9) in cohort A vs. 86.6% (95% CI: 77.8–96.4) in cohort B (p = 0.11). Event-free survival was 92.9% (95% CI: 88.2–97.8) vs. 86.8% (95% CI: 78-96.4) (p = 0.29). Conclusion: Partial substitution of cisplatin with cyclophosphamide showed a better toxicity profile, particularly for ototoxicity and neurotoxicity, with no significant difference in survival.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Diagnoses of children with CNS tumors according to the International Classification of Childhood Cancer (ICCC), third edition (ICCC-3). We annotated our cases according to ICCC-3 which is based on ICD-O-3 codes for both topographies and morphologies, to categorize childhood cancers.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Diagnoses of children with CNS tumors according to the International Classification of Childhood Cancer (ICCC), third edition (ICCC-3). We annotated our cases according to ICCC-3 which is based on ICD-O-3 codes for both topographies and morphologies, to categorize childhood cancers.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Background:Central nervous system (CNS) tumors are the leading cause of cancer-related deaths in children. Although most cases come from low- and middle-income countries (LMIC) where their prognosis is worse, few epidemiologic studies are conducted in these regions.Methods:We conducted a registry-based cohort study for childhood CNS tumors at Children’s Cancer Hospital, Egypt, over 15 years. Unified treatment protocols were implemented. Survival analyses were conducted using the Kaplan–Meier function. Cases were additionally annotated using the International Classification of Childhood Cancer-3 classification.Results:In total, 5,051 children ≤18 years of age were identified, accounting for 20% of all childhood cancers treated at Children’s Cancer Hospital, Egypt. The most common tumor sites were the posterior fossa (36.8%) and brainstem (17.7%). Pathologies were predominantly astrocytic (n = 1,360; 26.9%) and embryonal (n = 1,003; 19.9%) in origin. The 5-year overall survival (OS) and event-free survival for all cases were 64.6% and 51.8%, respectively. More specifically, 1,421 low-grade gliomas were identified, with a 5-year OS of 91.1%. Medulloblastoma (n = 801) recorded a 5-year OS of 66%. The entity with the worst prognosis was diffuse intrinsic pontine glioma (n = 633), with a 5-year OS of 3.2%.Conclusions:We report on a large number of childhood CNS tumors from an LMIC. This study underscores the need to understand the burden of childhood brain tumors and its outcomes in resource-constrained settings.Impact:This study reports on the epidemiology and clinical outcomes of 5,000+ children with CNS tumors from a specialized LMIC center. Despite the lack of many sophisticated and advanced facilities, LMICs can improve the clinical end-results with experience and augmented efforts.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Background:Central nervous system (CNS) tumors are the leading cause of cancer-related deaths in children. Although most cases come from low- and middle-income countries (LMIC) where their prognosis is worse, few epidemiologic studies are conducted in these regions.Methods:We conducted a registry-based cohort study for childhood CNS tumors at Children’s Cancer Hospital, Egypt, over 15 years. Unified treatment protocols were implemented. Survival analyses were conducted using the Kaplan–Meier function. Cases were additionally annotated using the International Classification of Childhood Cancer-3 classification.Results:In total, 5,051 children ≤18 years of age were identified, accounting for 20% of all childhood cancers treated at Children’s Cancer Hospital, Egypt. The most common tumor sites were the posterior fossa (36.8%) and brainstem (17.7%). Pathologies were predominantly astrocytic (n = 1,360; 26.9%) and embryonal (n = 1,003; 19.9%) in origin. The 5-year overall survival (OS) and event-free survival for all cases were 64.6% and 51.8%, respectively. More specifically, 1,421 low-grade gliomas were identified, with a 5-year OS of 91.1%. Medulloblastoma (n = 801) recorded a 5-year OS of 66%. The entity with the worst prognosis was diffuse intrinsic pontine glioma (n = 633), with a 5-year OS of 3.2%.Conclusions:We report on a large number of childhood CNS tumors from an LMIC. This study underscores the need to understand the burden of childhood brain tumors and its outcomes in resource-constrained settings.Impact:This study reports on the epidemiology and clinical outcomes of 5,000+ children with CNS tumors from a specialized LMIC center. Despite the lack of many sophisticated and advanced facilities, LMICs can improve the clinical end-results with experience and augmented efforts.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Detailed diagnoses by pathology. The pathological subtypes discussed in the study are presented in more detail with all the histological diagnoses and their grade.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Detailed diagnoses by pathology. The pathological subtypes discussed in the study are presented in more detail with all the histological diagnoses and their grade.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Detailed pathological diagnosis for all childhood CNS tumors included in the cohort. Bars represent the count of each subtype. Pilocytic astrocytoma was the most common subtype.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Detailed pathological diagnosis for all childhood CNS tumors included in the cohort. Bars represent the count of each subtype. Pilocytic astrocytoma was the most common subtype.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Survival analysis by subgroups reclassified based on the International Classification of Childhood Cancer (ICCC), third edition (ICCC-3). Five-year overall and event-free survival alongside their 95% CIs.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Epidemiology and Clinical Outcomes of Childhood Central Nervous System Cancers in a Large Low/Middle-Income Country Pediatric Oncology Center: A Report on 5,051 Kids
Survival analysis by subgroups reclassified based on the International Classification of Childhood Cancer (ICCC), third edition (ICCC-3). Five-year overall and event-free survival alongside their 95% CIs.